INCRUSE ELLIPTA Inhaler / Dry Powder
Umeclidinium as (bromide)
62.5mcg/Dose (74.2 mcg/Dose)
GLAXO GROUP LIMITED
| Pack size | 1 Inhaler (30 doses) |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | AL ITTIHAD DRUG STORE |
| Retail Price | 180.50 AED |
Indications
INCRUSE ELLIPTA Inhaler / Dry Powder is used for:
Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Umeclidinium as (bromide) :
Mechanism of Action
Umeclidinium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through the inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
Note
INCRUSE ELLIPTA 62.5mcg/Dose (74.2 mcg/Dose) Inhaler / Dry Powder manufactured by GLAXO GROUP LIMITED. Its generic name is Umeclidinium as (bromide). INCRUSE ELLIPTA is availble in United Arab Emirates.
Farmaco UAE drug index information on INCRUSE ELLIPTA Inhaler / Dry Powder is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.